Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ)
CNY 12.14
(2.53%)
CNY 12.14
(2.53%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.43 Billion CNY | -1.02% |
| 2022 | 2.45 Billion CNY | -28.72% |
| 2021 | 3.44 Billion CNY | -12.98% |
| 2020 | 3.96 Billion CNY | 47.72% |
| 2019 | 2.68 Billion CNY | -25.99% |
| 2018 | 3.62 Billion CNY | 4.42% |
| 2017 | 3.47 Billion CNY | 47.76% |
| 2016 | 2.34 Billion CNY | 334.23% |
| 2015 | 540.97 Million CNY | -53.84% |
| 2014 | 1.17 Billion CNY | 3.72% |
| 2013 | 1.12 Billion CNY | -4.96% |
| 2012 | 1.18 Billion CNY | 257.51% |
| 2011 | 332.5 Million CNY | 9.92% |
| 2010 | 302.5 Million CNY | 65.3% |
| 2009 | 183 Million CNY | 16.93% |
| 2008 | 156.5 Million CNY | 13.08% |
| 2007 | 138.4 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 2.02 Billion CNY | -12.31% |
| 2024 Q1 | 2.41 Billion CNY | -0.67% |
| 2024 Q2 | 2.34 Billion CNY | -3.01% |
| 2023 Q4 | 2.43 Billion CNY | -0.97% |
| 2023 FY | 2.43 Billion CNY | -1.02% |
| 2023 Q1 | 2.5 Billion CNY | 1.96% |
| 2023 Q2 | 2.46 Billion CNY | -1.6% |
| 2023 Q3 | 2.45 Billion CNY | -0.37% |
| 2022 Q4 | 2.45 Billion CNY | -5.27% |
| 2022 FY | 2.45 Billion CNY | -28.72% |
| 2022 Q2 | 3.32 Billion CNY | -4.57% |
| 2022 Q3 | 2.59 Billion CNY | -21.9% |
| 2022 Q1 | 3.48 Billion CNY | 0.96% |
| 2021 Q3 | 3.15 Billion CNY | -9.14% |
| 2021 FY | 3.44 Billion CNY | -12.98% |
| 2021 Q4 | 3.44 Billion CNY | 9.41% |
| 2021 Q1 | 3.56 Billion CNY | -10.14% |
| 2021 Q2 | 3.46 Billion CNY | -2.58% |
| 2020 Q1 | 3.99 Billion CNY | 49.06% |
| 2020 Q4 | 3.96 Billion CNY | -5.83% |
| 2020 FY | 3.96 Billion CNY | 47.72% |
| 2020 Q2 | 4.15 Billion CNY | 3.8% |
| 2020 Q3 | 4.2 Billion CNY | 1.38% |
| 2019 Q3 | 3.13 Billion CNY | -2.8% |
| 2019 Q4 | 2.68 Billion CNY | -14.54% |
| 2019 Q1 | 3.72 Billion CNY | 2.7% |
| 2019 Q2 | 3.22 Billion CNY | -13.25% |
| 2019 FY | 2.68 Billion CNY | -25.99% |
| 2018 Q1 | 3.57 Billion CNY | 2.87% |
| 2018 Q3 | 3.76 Billion CNY | -3.41% |
| 2018 FY | 3.62 Billion CNY | 4.42% |
| 2018 Q4 | 3.62 Billion CNY | -3.79% |
| 2018 Q2 | 3.9 Billion CNY | 9.24% |
| 2017 Q2 | 2.88 Billion CNY | 15.02% |
| 2017 Q3 | 3.01 Billion CNY | 4.19% |
| 2017 Q4 | 3.47 Billion CNY | 15.3% |
| 2017 FY | 3.47 Billion CNY | 47.76% |
| 2017 Q1 | 2.51 Billion CNY | 6.94% |
| 2016 Q1 | 561.24 Million CNY | 3.75% |
| 2016 FY | 2.34 Billion CNY | 334.23% |
| 2016 Q4 | 2.34 Billion CNY | -17.62% |
| 2016 Q2 | 1.01 Billion CNY | 81.42% |
| 2016 Q3 | 2.85 Billion CNY | 180.06% |
| 2015 Q1 | 1.17 Billion CNY | 0.62% |
| 2015 Q4 | 540.97 Million CNY | -8.26% |
| 2015 FY | 540.97 Million CNY | -53.84% |
| 2015 Q2 | 1.16 Billion CNY | -1.25% |
| 2015 Q3 | 589.7 Million CNY | -49.36% |
| 2014 Q3 | 1.18 Billion CNY | -6.68% |
| 2014 Q2 | 1.26 Billion CNY | 5.25% |
| 2014 Q1 | 1.2 Billion CNY | 6.66% |
| 2014 FY | 1.17 Billion CNY | 3.72% |
| 2014 Q4 | 1.17 Billion CNY | -0.99% |
| 2013 Q1 | 1.18 Billion CNY | -0.4% |
| 2013 FY | 1.12 Billion CNY | -4.96% |
| 2013 Q2 | 1.04 Billion CNY | -11.38% |
| 2013 Q4 | 1.12 Billion CNY | -7.65% |
| 2013 Q3 | 1.22 Billion CNY | 16.59% |
| 2012 FY | 1.18 Billion CNY | 257.51% |
| 2012 Q1 | 362.5 Million CNY | 9.02% |
| 2012 Q2 | 460 Million CNY | 26.9% |
| 2012 Q3 | 610 Million CNY | 32.61% |
| 2012 Q4 | 1.18 Billion CNY | 94.87% |
| 2011 Q3 | 345 Million CNY | 2.99% |
| 2011 Q1 | 177.5 Million CNY | -41.32% |
| 2011 FY | 332.5 Million CNY | 9.92% |
| 2011 Q4 | 332.5 Million CNY | -3.62% |
| 2011 Q2 | 335 Million CNY | 88.73% |
| 2010 Q3 | 285 Million CNY | 5.17% |
| 2010 FY | 302.5 Million CNY | 65.3% |
| 2010 Q2 | 271 Million CNY | 0.0% |
| 2010 Q4 | 302.5 Million CNY | 6.14% |
| 2009 Q4 | 183 Million CNY | 0.0% |
| 2009 FY | 183 Million CNY | 16.93% |
| 2008 FY | 156.5 Million CNY | 13.08% |
| 2007 FY | 138.4 Million CNY | 0.0% |